References 1 Mendelsohn J . Targeting the epidermal growth factor receptor for cancer therapy . J Clin Oncol 2002 ; 20 : 1s – 13s . 2 Castillo L Etienne-Grimaldi MC Fischel JL . Pharmacological background of EGFR
Search Results
NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer
Barbara Burtness, Milan Anadkat, Surendra Basti, Miranda Hughes, Mario E. Lacouture, Joan S. McClure, Patricia L. Myskowski, Jennifer Paul, Clifford S. Perlis, Leonard Saltz, and Sharon Spencer
Economic Analysis of Exclusionary EGFR Test Versus Up-Front NGS for Lung Adenocarcinoma in High EGFR Mutation Prevalence Areas
Szu-Chun Yang, Yi-Chen Yeh, Yi-Lin Chen, and Chao-Hua Chiu
Cancer, 3 patients with newly diagnosed metastatic lung adenocarcinoma are recommended to be tested for mutations in 8 driver genes, including EGFR , ALK , ROS1 , BRAF , RET , MET , NTRK , and KRAS , because FDA-approved therapies are available
Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis
Zi-Xian Wang, Hao-Xiang Wu, Ming-Ming He, Ying-Nan Wang, Hui-Yan Luo, Pei-Rong Ding, Dan Xie, Gong Chen, Yu-Hong Li, Feng Wang, and Rui-Hua Xu
–epidermal growth factor receptor (EGFR) agents (Cet/Pani) compared with chemotherapy alone in relation to PTL in patients with RAS wt mCRC. Patients and Methods This meta-analysis was reported in accordance with PRISMA guidelines. 20 Study Selection and Data
Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer
Jeremy D. Kratz, Nataliya V. Uboha, Sam J. Lubner, Daniel L. Mulkerin, Linda Clipson, Yanyao Yi, Menggang Yu, Kristina A. Matkowskyj, Noelle K. LoConte, and Dustin A. Deming
chemotherapy and targeted agents depending on distinct molecular profiles. Antibodies targeting epidermal growth factor receptor (EGFR), including cetuximab and panitumumab, have shown clinical utility in the late-line setting. 3 , 4 Defining populations most
Predictive Biomarkers for Anti-Epidermal Growth Factor Receptor Therapy: Beyond KRAS Testing
Noman Ashraf, Nishi Kothari, and Richard Kim
mutations, and how these data may impact clinical decision-making Identify established predictive markers for cetuximab and panitumumab Discuss the clinical implications of data regarding potential new biomarkers for anti-EGFR therapy Colorectal
HSR22-124: Real-World Outcomes Among Patients With Stage IV Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer Treated With EGFR Tyrosine Kinase Inhibitors Versus Immunotherapy With or Without Chemotherapy in First-line Setting
Jon Apple, Rahul Shenolikar, Kevin De Silva, Ping Sun, and Alexander Spira
Background : Current national guidelines recommend epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line (1L) for EGFR mutated metastatic non-small cell lung cancer (EGFRm mNSCLC) patients. Depending on the
Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations
Joshua K. Sabari, John V. Heymach, and Beth Sandy
mutation status. 2 , 3 The most frequently altered genes in NSCLC are EGFR (10%–35%), KRAS (25%–30%), FGR (20%), ALK (3%–7%), MET (2%–4%), BRAF (1%–3%), ROS1 (1%–3%), and RET (1%–3%). 2 , 3 For many of the molecular subsets, including
Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer
Rogerio A. Lilenbaum and Leora A. Horn
The identification of molecular targets and the development of agents to treat those targets has changed the paradigm for the management of non–small cell lung cancer (NSCLC). “The progress in NSCLC has been absolutely amazing. EGFR and KRAS
A Patient With Metastatic Lung Adenocarcinoma Harboring Concurrent EGFR L858R, EGFR Germline T790M, and PIK3CA Mutations: The Challenge of Interpreting Results of Comprehensive Mutational Testing in Lung Cancer
Philip E. Lammers, Christine M. Lovly, and Leora Horn
testing of exons 18-21 of the epidermal growth factor receptor ( EGFR) gene performed at an outside institution revealed the presence of both an EGFR L858R missense mutation in exon 21 and a T790M point mutation in exon 20. His local oncologist was
EGFR-Mutant Non–Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing
Ammar Sukari, Misako Nagasaka, and Erin Wakeling
-capture–selected libraries are sequenced to high uniform depth (targeting >500x coverage by non-PCR duplicate read pairs, with >99% exons at coverage >100x) on the Illumina HiSeq2000 sequencing platform. 1 Genomic DNA isolation and EGFR T790M real-time PCR was performed
